vaultfert.blogg.se - Antidote for ativan overdose

Information in the boxed warning for all IR and ER/LA opioid pain medicines will be updated and reordered to elevate the importance of warnings concerning life-threatening respiratory depression, and risks associated with using opioid pain medicines in conjunction with benzodiazepines or other medicines that depress the central nervous system (CNS).This includes information describing the symptoms that differentiate OIH from opioid tolerance and withdrawal.

A new warning is being added about opioid-induced hyperalgesia (OIH) for both IR and ER/LA opioid pain medicines.

Updates to the ER/LA opioids recommend that these drugs be reserved for severe and persistent pain requiring an extended period of treatment with a daily opioid pain medicine and for which alternative treatment options are inadequate.

Updates to the IR opioids state that these drugs should not be used for an extended period unless the pain remains severe enough to require an opioid pain medicine and alternative treatment options are insufficient, and that many acute pain conditions treated in the outpatient setting require no more than a few days of an opioid pain medicine.

The changes apply to both immediate-release (IR) and extended-release/long-acting preparations (ER/LA). The changes are being made to provide additional guidance for safe use of these drugs while also recognizing the important benefits when used appropriately.

As part of its ongoing efforts to address the nation's opioid crisis, FDA is requiring several updates to the prescribing information of opioid pain medicines.